For these reasons, patients with SSc-PAH are often denied the LT option. However, if properly screened and approved for LT, patients with SSc experience similar rates of survival 2 years after the ...

Bosentan is known to be effective for SSc-associated pulmonary arterial hypertension (PAH), but data regarding long-term outcomes are scarce. In addition, although it has been shown to prevent the ...

Some small series have reported 6-month post-transplant survival of 69% for selected patients with SSc-PAH compared with 79% for iPAH, with early deaths related to primary graft dysfunction and ...

This is followed by specific recommendations for people whose SSc causes ulcers on their fingers, then those with pulmonary ...